Skip to main content

Ciphergen Q4 Revenues Slide 35 Percent as Profit Turns to Loss

NEW YORK, Feb. 17 (GenomeWeb News) - Ciphergen yesterday reported that its fourth-quarter sales fell 35 percent to $6.6 million from $10.1 million during the year-ago period, as net income fell into the red.

 

Research and development costs fell to $3 million from $3.7 million a year ago.

 

Ciphergen reported a net loss of $9.2 million, or $0.26 per share, versus a net income of $10.3 million, or $0.35, in the fourth quarter of 2004. The company said the results included a $2.5-million non-cash charge for the impairment of goodwill.

 

As of Dec. 31, the company had $25.7 million in cash and cash equivalents.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.